Body

Successful treatment of triple negative breast cancer by modulation of the OGF-OGFr axis

Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells to inhibit proliferation. According to BreastCancer.org 1 in 8 women in the U.S. will develop invasive breast cancer and more than 39,000 deaths occur annually.

Whole-genome sequencing uncovers the mysteries of the endangered Chinese alligator

August 9, 2013, Shenzhen, China - In a study published in Cell Research, Chinese scientists from Zhejiang University and BGI have completed the genome sequencing and analysis of the endangered Chinese alligator (Alligator sinensis). This is the first published crocodilian genome, providing a good explanation of how terrestrial-style reptiles adapt to aquatic environments and temperature-dependent sex determination (TSD).

New treatment for brittle bone disease found

A new treatment for children with brittle bone disease has been developed by the University of Sheffield and Sheffield Children's Hospital.

The study of the new treatment for children with the fragile bone disease Osteogenesis Imperfecta was published this week in the world's leading general medical journal, The Lancet.

New hope for improved TB treatments

Researchers at the University of Southampton have identified new markers of tuberculosis (TB) that may help in the development of new diagnostic tests and treatments.

Published online in the Journal of Infectious Diseases, the study investigated the proteins that are released by a break down of the lung structure in TB patients. Lung damage causes both transmission of infection and mortality.

Typical protein profile of tumor cells decoded

In what is the biggest study of its kind to date, researchers from Technische Universität München (TUM) have identified over 10,000 different proteins in cancer cells. "Nearly all anti-tumor drugs are targeted against cellular proteins," says Prof. Bernhard Küster, Head of the TUM Chair of Proteomics and Bioanalytics. "Identifying the proteome the protein portfolio of tumor cells increases our chances of finding new targets for drugs."

Tahiti: A very hot biodiversity hot spot in the Pacific

A collaborative biological survey that focused on the insects of French Polynesia has resulted in the discovery of over 100 tiny predatory beetle species in Tahiti, 28 of these species newly described in the open-access journal ZooKeys.

Moffitt researchers identify gene variations that may help predict cancer treatment response

Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in non-small cell lung cancer patients that can help predict survival and treatment response. Their findings could help lead to more personalized treatment options and improved outcomes for patients.

Telemedicine consultations significantly improve pediatric care in rural emergency rooms

Telemedicine consultations with pediatric critical-care medicine physicians significantly improve the quality of care for seriously ill and injured children treated in remote rural emergency rooms, where pediatricians and pediatric specialists are scarce, a study by researchers at UC Davis Children's Hospital has found.

How to achieve a well-balanced gut

Creating an environment that nurtures the trillions of beneficial microbes in our gut and, at the same time, protects us against invasion by food-borne pathogens is a challenge. A study published on August 8 in PLOS Pathogens reveals the role of a key player in this balancing act.

Study reveals role of 'peacekeeper' in the gut

A new study has shone a spotlight on the peacekeeping mechanisms in our intestines.

A protein, called SIGIRR, is produced by the cells that line the intestines. It supresses the cells' immune response to bacteria.

With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?

Generally, FDA-approved clinical trials progress through three phases: the first shows safety, the second starts to explore effects and the third seeks to prove a drug's superiority over existing treatments. But when a drug's benefit is obvious in the first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.

Faith-based re-entry program for prisoners saves money, reduces recidivism, Baylor study finds

A faith-based prisoner re-entry program in Minnesota has saved an estimated $3 million by reducing recidivism, according to a Baylor University study published in the International Journal of Criminology and Sociology.

The study is a cost-benefit analysis of the InnerChange Freedom Initiative, a program which relies heavily on volunteers and is privately funded, said study co-author Byron Johnson, Ph.D., co-director of Baylor's Institute for Studies of Religion (ISR).

A path to better MTV-MOFs

Scientists would like to apply the same principles by which baking soda removes food odors from refrigerators or silica powder keeps moisture away from electronic devices to scrub carbon dioxide from the exhaust gases of fossil fuel power plants. An excellent candidate for this task is the class of materials known as multivariate metal organic frameworks or MTV-MOFs, which were discovered by Omar Yaghi, one of the world's most cited chemists. However, finding and synthesizing the best MTV-MOFs for this task has been a major challenge. That discouraging state-of-affairs is about to change.

HSCI researchers extend human epigenomic map

Ten years ago, scientists announced the end of the Human Genome Project, the international attempt to learn which combination of four nucleotides—adenine, thymine, cytosine, and guanine—is unique to homo sapien DNA. This biological alphabet helped researchers identify the approximately 25,000 genes coded in the human genome, but as time went on, questions arose about how all of these genes are controlled.

Scripps Research Institute study shows microRNAs can trigger lymphomas

LA JOLLA, CA—August 8, 2012—A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).

The six "microRNA" molecules were already known to be overproduced in lymphomas and in many other human cancers, but no one had demonstrated that they can be the prime cause of such cancers—until now. The new study also identified the major biological pathways through which these microRNAs ignite and maintain cancerous growth.